Feb 19, 2026 12:16PM
Feb 12, 2026 07:01AM
Feb 10, 2026 08:04AM
Jan 27, 2026 09:25AM
Oct 30, 2025 04:23PM
Aug 7, 2025 05:44PM
Aug 4, 2025 12:13PM Raymond James Reiterates Market Perform Rating on INmune Bio Inc. (INMB)
Aug 4, 2025 08:14AM
Jun 30, 2025 04:37PM
Jun 30, 2025 04:01PM
Jun 30, 2025 02:24PM
Jun 30, 2025 01:49PM
Jun 30, 2025 10:36AM
Jun 30, 2025 07:30AM INmune Bio (INMB) Reports Key Findings from Phase 2 MINDFuL Trial of XPro
Jun 27, 2025 12:16PM
Jun 26, 2025 04:42PM
Jun 26, 2025 04:01PM
Jun 24, 2025 10:47AM
Jun 23, 2025 10:53AM
Jun 10, 2025 04:02PM
Jun 4, 2025 06:18AM Lucid Capital Markets Starts INmune Bio Inc. (INMB) at Buy
May 8, 2025 04:14PM
Apr 16, 2025 07:01AM
Apr 1, 2025 07:02AM
Mar 31, 2025 04:54AM
Feb 12, 2025 07:03AM
Feb 12, 2025 05:12AM
Feb 11, 2025 06:53AM INmune Bio Inc. (INMB) PT Raised to $23 at Scotiabank
Feb 10, 2025 07:03AM
Jan 28, 2025 10:26AM
Jan 28, 2025 08:05AM
Jan 28, 2025 06:31AM
Oct 31, 2024 04:12PM
Sep 26, 2024 08:01AM
Sep 18, 2024 09:14AM Scotiabank Reiterates Sector Outperform Rating on INmune Bio Inc. (INMB)
Sep 18, 2024 06:22AM
Sep 17, 2024 08:31AM
Sep 13, 2024 08:31AM
Aug 22, 2024 07:38AM
Aug 2, 2024 04:03PM
Aug 1, 2024 04:51PM
Jul 29, 2024 09:00AM INmune Bio (INMB) Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer’s Patients
Jul 23, 2024 08:45AM

353,174 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All